SOX13

SOX13 is a SoxD-family HMG-box transcription factor that binds the SOX consensus motif and controls cell-fate and inflammatory programs across immune, neural, vascular, and cancer contexts (PMID:10871192, PMID:17218525). Its DNA-binding behavior is gated by dimerization: a coiled-coil/leucine-zipper domain mediates homodimerization, which inhibits DNA binding, so productive activity favors heterodimer formation (e.g., with Sox5) (PMID:10871192, PMID:32461589). A central, well-established role is as a lineage-specifying factor for IL-17-committed γδ T cells (γδT17) in the thymus: SOX13 promotes γδ T cell development while opposing αβ fate, acts together with TCF1 to program TCR-independent γδT17 progenitors, and a loss-of-function mutation selectively ablates Vγ4+ γδT17 cells and protects from psoriasis-like dermatitis (PMID:17218525, PMID:23624556, PMID:30413363). SOX13 represses Wnt/TCF signaling by interacting with TCF1, an interaction antagonized by Hhex, which displaces SOX13 from the SOX13×TCF1 complex (PMID:17218525, PMID:20028982). In endothelial cells, SOX13 is a flow-sensitive anti-inflammatory factor that represses the chemokines CXCL10 and CCL5 under laminar shear stress (PMID:36247423). In cancer, SOX13 functions as a promoter-binding transactivator of effector genes—driving SNAI2/MET, Twist1, TRIM11, SPON2/FUS, LRP11, and SCAF1—to promote metastasis, EMT, angiogenesis, immune evasion, and, via SCAF1-dependent mitochondrial supercomplex assembly, ferroptosis resistance (PMID:32111984, PMID:32461589, PMID:33613102, PMID:38769295, PMID:30736838).

1. 1998 Medium

   Establishing SOX13's domain architecture and DNA-binding capacity defined it as an HMG-box factor with dimerization potential but no intrinsic transactivation on a simple motif concatamer.

   Evidence Cloning/sequence analysis with DNA-binding and reporter assays

   PMID:9421502

   Open questions at the time

   • No physiological target promoter tested
   • Cofactor requirements for transactivation not identified
2. 2000 Medium

   Demonstrating that homodimerization inhibits DNA binding revealed that SOX13 activity is gated by dimer state, implying heterodimer formation is needed for nuclear function.

   Evidence Recombinant protein DNA-binding assays with epitope/deletion mapping and immunohistochemistry

   PMID:10871192

   Open questions at the time

   • Heterodimer partners not identified in this study
   • Structural basis of dimer-mediated inhibition unresolved
3. 2007 High

   Reciprocal mouse genetics placed SOX13 as a γδ T cell lineage determinant acting through repression of Wnt/TCF signaling via TCF1, defining its first in vivo developmental pathway.

   Evidence Sox13 transgenic and knockout mice with Wnt/TCF reporter epistasis

   PMID:17218525

   Open questions at the time

   • Direct transcriptional targets in γδ T cells not enumerated
   • Mechanism of TCF1 inhibition at chromatin not resolved
4. 2009 High

   Identifying Hhex as a direct SOX13 partner that displaces SOX13 from TCF1 explained how SOX13-mediated Wnt repression is reversed, adding a regulatory layer to the pathway.

   Evidence Yeast two-hybrid, co-IP domain mapping, Wnt/TCF reporter assays, and embryo electroporation

   PMID:20028982

   Open questions at the time

   • Physiological contexts where Hhex competition operates not fully mapped
   • Stoichiometry of SOX13/TCF1/Hhex complex unknown
5. 2013 High

   A natural loss-of-function mutation showed the γδT17 defect is intrinsic and disease-relevant, linking SOX13 to inflammatory dermatitis.

   Evidence Natural mutant substrain mapping and thymic developmental assays plus psoriasis-like disease model

   PMID:23624556

   Open questions at the time

   • Downstream effector genes of SOX13 in γδT17 cells not defined
   • Human relevance of the murine mutation not established
6. 2018 High

   Reporter knock-in and scRNA-seq established that SOX13/TCF1 program γδT17 progenitors independently of TCR signaling, clarifying the timing and logic of lineage commitment.

   Evidence SOX13 reporter mice, thymic organ culture, and scRNA-seq of TCR-deficient mice

   PMID:30413363

   Open questions at the time

   • Direct chromatin targets of the SOX13/TCF1 program not identified
   • How SOX13 cooperates mechanistically with TCF1 at target loci unresolved
7. 2015 Medium

   Comparing SOX13 to Sox5/Sox6 in oligodendrocytes showed functional redundancy: it antagonizes Sox10-dependent myelin gene activation but is dispensable alone, revealing context-dependent SoxD redundancy.

   Evidence In vitro DNA binding, reporter assays, and Sox6/Sox13 double-knockout mice

   PMID:26525805

   Open questions at the time

   • Direct SOX13 myelin targets in vivo not confirmed
   • Extent of SOX13/Sox6 redundancy across other lineages unknown
8. 2019 Medium

   Multiple cancer studies began defining SOX13 as a direct promoter-binding transactivator of effector genes (SPON2, FUS, PAX8), extending its role beyond development into proliferation and angiogenesis.

   Evidence ChIP, dual-luciferase, RNA pulldown/RNA-IP, and knockdown/rescue functional assays in glioma and gastric cancer cells

   PMID:30736838 PMID:31353958

   Open questions at the time

   • PAX8 axis lacks direct promoter/ChIP confirmation (Low confidence)
   • In vivo relevance of these axes limited
9. 2020 Medium

   Mechanistic cancer studies defined direct SOX13 transcriptional targets driving metastasis/EMT and embedded SOX13 in upstream signaling, including HGF/STAT3 and Sox5 heterodimerization.

   Evidence ChIP, mutagenesis reporter assays, co-IP heterodimer detection, and invasion/rescue assays in colorectal and hepatocellular carcinoma

   PMID:32111984 PMID:32461589

   Open questions at the time

   • Whether SNAI2/MET/Twist1 are conserved targets across tissues unknown
   • Relative contribution of homo- vs heterodimer to each target unresolved
10. 2021 Medium

    Linking SOX13 to TRIM11 transactivation connected it to YAP/Hippo signaling via ubiquitin-mediated YAP stabilization, broadening its oncogenic output.

    Evidence Promoter-luciferase, co-IP, ubiquitination IP, and functional assays in anaplastic thyroid cancer

    PMID:33613102

    Open questions at the time

    • Direct SOX13 binding site on TRIM11 promoter not finely mapped
    • Generality of the SOX13→TRIM11→YAP axis beyond thyroid cancer unknown
11. 2022 Medium

    Identifying SOX13 as a flow-sensitive anti-inflammatory endothelial factor that represses CXCL10/CCL5 added a vascular homeostatic role distinct from its developmental functions.

    Evidence Reciprocal siRNA/overexpression, RNA-seq under shear, ELISA, and scRNA/scATAC of carotid ligation model

    PMID:36247423

    Open questions at the time

    • Direct binding to CXCL10/CCL5 regulatory regions not demonstrated
    • Upstream flow-sensing mechanism controlling SOX13 expression unknown
12. 2024 High

    Defining the SOX13→SCAF1→mitochondrial supercomplex axis established a metabolic mechanism for ferroptosis resistance and a druggable degradation strategy via zanamivir/TRIM25.

    Evidence ChIP/transactivation, supercomplex and respiration assays, molecular docking, ubiquitination assays, and xenografts in gastric cancer

    PMID:38769295

    Open questions at the time

    • Whether SCAF1 is the dominant ferroptosis-relevant target unresolved
    • Selectivity of zanamivir for SOX13 in vivo not fully characterized
13. 2024 Low

    Placing SOX13 upstream of LRP11/β-catenin/PD-L1 implicated it in tumor immune evasion via CD8+ T cell suppression.

    Evidence Promoter-binding and gain-of-function assays, CD8+ T cell co-culture, and allograft models in breast cancer

    PMID:39243917

    Open questions at the time

    • ChIP/mutagenesis details for LRP11 promoter not described
    • Direct vs indirect activation of LRP11 not distinguished
14. 2025 Medium

    Identifying SOX13 as a POU3F2 target mediating canonical Wnt signaling in human neural progenitors extended its developmental role to NPC proliferation and radial glia timing.

    Evidence POU3F2 disruption in human NPCs with unbiased target analysis and Wnt reporter/proliferation assays

    PMID:40498903

    Open questions at the time

    • Direct SOX13 targets in NPCs not defined
    • Whether SOX13 activates or represses Wnt here vs its repressive role in T cells unresolved

• How dimer-state gating, partner choice (Sox5, TCF1, Hhex), and context determine whether SOX13 activates or represses a given target across its diverse developmental, vascular, and oncogenic roles remains unresolved.
• No genome-wide direct target map across cell types
• No structural model of SOX13 dimer/heterodimer on DNA
• Rules governing activation vs repression switching unknown